Package leaflets of medicines distributed within the European Union should use the template headings and standard texts created by the Working Group on the Quality Review of Documents (QRD). The following study investigated how the QRD template is implemented in this patient information.
Methods:
All English-language package leaflets available on the European Medicines Agency website for centralized authorization procedures were downloaded 3 times, separated by a time period of 1 year. A catalog of criteria was applied to analyze QRD template text use.
Results:
Because of the rapid implementation of updates, the template text used in each package leaflet (N = 565) increased from an average of 444 words in the first download to 565 words during the 2 subsequent years. With template version 7, the fraction of template text per leaflet was 19.7% in 2011, which increased to 21.5% in 2013 with implementation of version 9.
Conclusions:
Limitation to mandatory contents through stricter use of the QRD template’s bracketing convention, which would reduce package leaflets’ text without loss of essential information, is suggested. In addition, making the current QRD template more concise is strongly recommended.
WeitbrechtWVoßkämperC. Influence of the drug package information paper on compliance of neurological and psychiatric outpatients. Fortschr Neurol Psychiatr. 2002;4:178–184.
2.
FuchsJBanowSGörbertNHippiusM. Importance of package insert information in the European Union. Pharm Ind. 2007;69(2):165–172.
Council of the European Communities, Council Directive 92/27/EEC of 31 March 1992 on the labelling of medicinal products for human use and on package leaflets. OJ1992, L 113: 107–114.
WolfA.An analysis and evaluation of the development of the QRD human product information template used in package leaflets [dissertation]. Faculty of Mathematics and Natural Sciences at the Rheinischen Friedrich-Wilhelms-University Bonn, 2015. http://hss.ulb.uni-bonn.de/2015/3934/3934.htm. Accessed April 17, 2015.
7.
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. OJ L. 2004;136:1.
8.
European Union. Consolidated versions of the treaty on European Union and of the treaty establishing the European community. OJ2006;C321
The European Parliament and the Council of the European Union. Directive 2010/84/EU of the European Parliament and the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Communities2010, L348:74–99.
11.
The European Parliament and the Council of the European Union. Regulation (EU) no. 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Regulation (EC) no. 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) no. 1394/2007 on advanced therapy medicinal products. OJ L. 2010;348:1–16.
12.
FuchsJScheunpflugCGötzeE. The influence of the European Union’s QRD template on the use of package inserts compared with a shorter model template. Pharm Ind. 2012;74(1):126–136.
13.
FuchsJ. The way forward in package insert user tests from a CRO’s perspective. Drug Inform J. 2010;44(2):119–129.
14.
FuchsJWernerSScheunpflugC. Excessive medical information increase in package inserts. Int J Clin Pharmacol Ther. 2010;48(12):781–790.
WolfAFuchsJSchweimH. QRD template texts intended for package inserts: Development from the first QRD template up to the new draft of July 2012. Pharm Ind. 2012;74(9):1540–1549.
17.
European Medicines Agency. QRD template versions 1 to 7.3.1. European Medicines Agency (http://www.ema.europa.eu/). Personal communication, July 2011.
WolfAFuchsJSchweimH. Readability of the European QRD Template - The European QRD template version 8 in comparison to its predecessor and a shorter model template. Pharm Ind. 2014;76(8):1312–1322.
24.
KnappPRaynorDKBerryDC. Comparison of two methods of presenting risk information to patients about the side effects of medicines. Qual Saf Health Care. 62004;13(3):176–180.
25.
European Commission. A guideline on the readability of the label and package leaflet of medicinal products for human use. Brussels: EC, September 29, 1998. http://pharma.be/assets/files/854/854_128901376878944246.pdf. Accessed August 11, 2015.
